(Q43700721)

English

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis

scientific article published on 22 May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Byung Woog Kang

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Tae Won Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Jae-Lyun Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Min-Hee Ryu

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Heung Moon Chang

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Chang Sik Yu

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Jin Cheon Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Jong Hoon Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Yoon-Koo Kang

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Jung Shin Lee

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

22 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

32-37

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor as a target for antiangiogenic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab for the treatment of colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surgical therapy for colorectal metastases to the liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine as third line therapy in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2008

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular and biological properties of vascular endothelial growth factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A systematic overview of chemotherapy effects in colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic therapy for colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18498064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-008-9077-8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43700721&oldid=2206211533"